CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...